Header Logo

Connection

HELEN HESLOP to T-Lymphocytes

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about T-Lymphocytes.
HELEN HESLOP
Connection Strength
9.631
T-Lymphocytes
  1. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
    View in: PubMed
    Score: 0.477
  2. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
    View in: PubMed
    Score: 0.360
  3. Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Mol Ther. 2019 05 08; 27(5):900-901.
    View in: PubMed
    Score: 0.318
  4. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. Cancer Immunol Res. 2019 04; 7(4):528-533.
    View in: PubMed
    Score: 0.317
  5. A backpack revs up T-cell activity. Nat Biotechnol. 2018 08 06; 36(8):702-703.
    View in: PubMed
    Score: 0.303
  6. Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277.
    View in: PubMed
    Score: 0.280
  7. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540.
    View in: PubMed
    Score: 0.273
  8. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016 06 30; 127(26):3331-40.
    View in: PubMed
    Score: 0.260
  9. Genetic engineering of T-cell receptors: TCR takes to titin. Blood. 2013 Aug 08; 122(6):853-4.
    View in: PubMed
    Score: 0.214
  10. Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5.
    View in: PubMed
    Score: 0.211
  11. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9.
    View in: PubMed
    Score: 0.176
  12. Safer CARS. Mol Ther. 2010 Apr; 18(4):661-2.
    View in: PubMed
    Score: 0.170
  13. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
    View in: PubMed
    Score: 0.169
  14. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
    View in: PubMed
    Score: 0.152
  15. Commentary on journal of immunotherapy paper by melenhorst et al. J Immunother. 2006 Jul-Aug; 29(4):365-6.
    View in: PubMed
    Score: 0.131
  16. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol. 2006 Jun; 84(3):281-9.
    View in: PubMed
    Score: 0.130
  17. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Nat Med. 2026 01; 32(1):258-269.
    View in: PubMed
    Score: 0.127
  18. Current status of genetic modification of T cells for cancer treatment. Cytotherapy. 2005; 7(3):262-72.
    View in: PubMed
    Score: 0.118
  19. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 01; 637(8047):940-946.
    View in: PubMed
    Score: 0.117
  20. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
    View in: PubMed
    Score: 0.114
  21. Moving CAR-Ts to the outpatient clinic. Br J Haematol. 2023 11; 203(4):507-508.
    View in: PubMed
    Score: 0.108
  22. Introduction to a How I Treat series on emergent CAR T-cell toxicities. Blood. 2023 05 18; 141(20):2405-2407.
    View in: PubMed
    Score: 0.106
  23. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
    View in: PubMed
    Score: 0.105
  24. Introduction to a review series on banked allogeneic immune effector cells. Blood. 2023 02 23; 141(8):811-812.
    View in: PubMed
    Score: 0.104
  25. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
    View in: PubMed
    Score: 0.102
  26. Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther. 2002 Oct; 4(5):467-75.
    View in: PubMed
    Score: 0.101
  27. Tumor-intrinsic causes of CAR-T failure. Blood. 2022 08 04; 140(5):414-415.
    View in: PubMed
    Score: 0.100
  28. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.
    View in: PubMed
    Score: 0.093
  29. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.092
  30. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.090
  31. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 02 10; 39(5):514-524.
    View in: PubMed
    Score: 0.090
  32. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
    View in: PubMed
    Score: 0.087
  33. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
    View in: PubMed
    Score: 0.087
  34. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.082
  35. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580.
    View in: PubMed
    Score: 0.082
  36. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218.
    View in: PubMed
    Score: 0.081
  37. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.077
  38. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.076
  39. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190.
    View in: PubMed
    Score: 0.076
  40. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.073
  41. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
    View in: PubMed
    Score: 0.073
  42. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
    View in: PubMed
    Score: 0.071
  43. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.071
  44. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.071
  45. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
    View in: PubMed
    Score: 0.070
  46. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148.
    View in: PubMed
    Score: 0.068
  47. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396.
    View in: PubMed
    Score: 0.067
  48. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704.
    View in: PubMed
    Score: 0.067
  49. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.065
  50. Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80.
    View in: PubMed
    Score: 0.065
  51. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
    View in: PubMed
    Score: 0.064
  52. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
    View in: PubMed
    Score: 0.063
  53. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
    View in: PubMed
    Score: 0.063
  54. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
    View in: PubMed
    Score: 0.062
  55. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73.
    View in: PubMed
    Score: 0.061
  56. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.061
  57. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.060
  58. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
    View in: PubMed
    Score: 0.060
  59. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.060
  60. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80.
    View in: PubMed
    Score: 0.058
  61. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74.
    View in: PubMed
    Score: 0.058
  62. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.057
  63. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.056
  64. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.056
  65. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.056
  66. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.056
  67. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.055
  68. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96.
    View in: PubMed
    Score: 0.054
  69. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.054
  70. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.054
  71. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62.
    View in: PubMed
    Score: 0.053
  72. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9.
    View in: PubMed
    Score: 0.048
  73. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.048
  74. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.047
  75. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.047
  76. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66.
    View in: PubMed
    Score: 0.047
  77. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267.
    View in: PubMed
    Score: 0.046
  78. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9.
    View in: PubMed
    Score: 0.045
  79. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20.
    View in: PubMed
    Score: 0.045
  80. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.043
  81. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am. 2010 Feb; 57(1):83-96.
    View in: PubMed
    Score: 0.042
  82. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.040
  83. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
    View in: PubMed
    Score: 0.040
  84. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008 Sep; 21(3):405-20.
    View in: PubMed
    Score: 0.038
  85. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
    View in: PubMed
    Score: 0.037
  86. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.035
  87. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
    View in: PubMed
    Score: 0.035
  88. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
    View in: PubMed
    Score: 0.033
  89. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
    View in: PubMed
    Score: 0.032
  90. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
    View in: PubMed
    Score: 0.031
  91. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
    View in: PubMed
    Score: 0.031
  92. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
    View in: PubMed
    Score: 0.030
  93. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.029
  94. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13.
    View in: PubMed
    Score: 0.029
  95. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 08 07; 32(8):2444-2460.
    View in: PubMed
    Score: 0.028
  96. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.028
  97. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
    View in: PubMed
    Score: 0.028
  98. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
    View in: PubMed
    Score: 0.028
  99. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
    View in: PubMed
    Score: 0.028
  100. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
    View in: PubMed
    Score: 0.028
  101. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
    View in: PubMed
    Score: 0.026
  102. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies. Transplant Cell Ther. 2023 04; 29(4):228-239.
    View in: PubMed
    Score: 0.026
  103. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.026
  104. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48.
    View in: PubMed
    Score: 0.026
  105. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53.
    View in: PubMed
    Score: 0.026
  106. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003; 331-49.
    View in: PubMed
    Score: 0.026
  107. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
    View in: PubMed
    Score: 0.025
  108. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201.
    View in: PubMed
    Score: 0.024
  109. Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022 02; 74:46-52.
    View in: PubMed
    Score: 0.024
  110. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422.
    View in: PubMed
    Score: 0.023
  111. CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996.
    View in: PubMed
    Score: 0.021
  112. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101.
    View in: PubMed
    Score: 0.020
  113. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.016
  114. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.014
  115. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
    View in: PubMed
    Score: 0.013
  116. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.011
  117. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.011
  118. The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. Acta Haematol. 1990; 83(4):203-5.
    View in: PubMed
    Score: 0.010
  119. T cell therapy in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):136-41.
    View in: PubMed
    Score: 0.009
  120. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
    View in: PubMed
    Score: 0.009
  121. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.008
  122. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41.
    View in: PubMed
    Score: 0.008
  123. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
    View in: PubMed
    Score: 0.007
  124. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
    View in: PubMed
    Score: 0.007
  125. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant. 2003 Jun; 31(11):981-6.
    View in: PubMed
    Score: 0.007
  126. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.